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CopyrigABSTRACT: Advances in systems biology in conjunction with the expansion in knowledge of drug
effects and diseases present an unprecedented opportunity to extend traditional pharmacokinetic
and pharmacodynamic modeling/analysis to conduct systems pharmacology modeling. Many drugs
that cause liver injury and myopathies have been studied extensively. Mitochondrion-centric systems
pharmacology modeling is important since drug toxicity across a large number of pharmacological
classes converges to mitochondrial injury and death. Approaches to systems pharmacology modeling
of drug effects need to consider drug exposure, organelle and cellular phenotypes across all key cell
types of human organs, organ-speciﬁc clinical biomarkers/phenotypes, gene–drug interaction and
immune responses. Systems modeling approaches, that leverage the knowledge base constructed
from curating a selected list of drugs across a wide range of pharmacological classes, will provide a
critically needed blueprint for making informed decisions to reduce the rate of attrition for drugs in
development and increase the number of drugs with an acceptable beneﬁt/risk ratio. Copyright ©
2013 John Wiley & Sons, Ltd.
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In addition to the designed on-target actions, med-
ications can inadvertently cause adverse drug
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Off-targets include transcription factors, enzymes,
receptors, RNAs and DNAs. Since multiple organs
are simultaneously exposed to a drug following ad-
ministration, one challenge is to better understand
why a drug can be more toxic or even sometimes
cause irreversible injury to a speciﬁc cell type and
leave others unaffected [1]. This gap is expected to
be bridged as sciences advance in the areas of imag-
ing mass spectrometry [2], panels of organ-speciﬁc
blood biomarkers [3], as well as pharmacokinetic
modeling of absorption, distribution, metabolism
and elimination (ADME) of drugs. Predicting rare
ADRs that occur in only 1 in 1000 to 1 in 1000000Received 30 July 2013
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2 J.P.F. BAI ET AL.users through traditional preclinical studies has
proven very challenging. Advanced technologies
now enable simultaneous multiplex measurements
of transcriptomic, proteomic and imaging read-
outs, as well as measurements of organelle and
cellular phenotypes [4]. Using these technologies
to reverse engineer the mechanisms for failure of
drugs in clinical trials may produce a useful
knowledge base wherein the respective molecu-
lar pathways leading to speciﬁc organelle/
cellular phenotypes can be matched to a particular
clinical phenotype.
In the era of informatics-accelerated health care
sciences, it is hoped that integration of systems
pharmacology-based modeling into drug devel-
opment could turn this notion into reality. Such
efforts will hopefully minimize drug attrition
throughout the life cycle of drug development.
Systems approaches to companion diagnostics for
more personalizedmedicinewill also hopefully help
more precisely to target drugs to the subpopulations
that are likely to experience the greatest clinical ben-
eﬁt and the lowest rate of ADRs [3]. This review pa-
per will focus on understanding and assessing drug
effects from a systems pharmacology perspective
with the hope of providing a reference framework
for efforts on improving drug safety.Systems Pharmacology Network of Drug
Linked to Clinical Phenotype/Biomarker
A drug can cause both on-target and off-target
perturbations at transcriptional [5], translational [6]
and post-translational levels – inciting its toxicolog-
ical networks in off-target organs (extended phar-
macological networks) [7] across the body and
inadvertently causing clinical presentations of
ADRs. From the knowledge accumulated with
both approved and withdrawn drugs, these net-
works are associated with the clinical phenotypes
and biomarkers manifested during therapy.
Systems pharmacology modeling has been used
for rare ADRs such as hypomagnesemia encoun-
tered with chronic use of proton pump inhibitors
(PPIs) [1,8]. Magnesium homeostasis is maintained
by intestinal absorption and renal excretion. Clini-
cal biomarkers of PPI-induced hypomagnesemia
include the elevation of serum Mg2+ concentration
and a decrease of 24h urinary secretion of Mg+Copyright © 2013 John Wiley & Sons, Ltd.respectively, followingde-challenge and re-challenge
with a PPI [8]. With these two markers as the guide,
an absorption-centric model was constructed to sim-
ulate the adverse impact of PPIs on oral absorption
and serum Mg2+ concentration [9]. In this model,
the reported off-target effect of PPIs leading to
reduced intestinal pH values in human subjects
was referenced [10], along with a corresponding
reduction in the availability of the TRPM6 binding
sites for Mg2+ as a result of intestinal pH reduction,
andMg2+ solubility in various intestinal pH values.
Such absorption-centric modeling reﬂected how a
minute daily reduction in oral absorption (1%
reduction) could lead to a substantial reduction
in the total body Mg2+ stores with resultant hypo-
magnesemia, following PPI use for 1 year or
longer. Both the intestinal and renal reabsorption
of magnesium involve paracellular absorption
facilitated by claudins [11], and active transport
mediated predominantly by transient receptor
potential melastin 6 (TRPM 6) [12]. The serum Mg2+
concentration and urinary secretion of Mg2+ were
associated with TRPM6 [12] and claudin 16 [13]
expression levels. Both serum concentration and
urinary secretion of Mg2+ increased and reduced,
respectively, in response to dietary load and restric-
tion and were correlated with down-regulation
and up-regulation of both TRPM6 and claudin 16
mRNAs. Such a regulated, synchronized interac-
tion between clinical biomarkers and organ trans-
port proteins (markers) in the intestine and
kidneys is an ideal case for an integrative systems
pharmacology modeling, where incorporation of
mechanistic renal elimination into the current
absorption-centric model to reﬂect, at the system
level, how these two organs work in concert to
maintain magnesium homeostasis.
A quite comprehensive systems pharmacology
model for predicting drug-induced liver injury is
DILIsym™ published by Howell et al. [14]. This
multi-scale model includes (1) biology systems at
the molecular (drug ADME processes, GSH dy-
namics, bile salt homeostasis), organelle (mitochon-
dria), cellular (energy balance and life cycle) and
system (clinical biomarkers) levels; (2) mechanistic
output of oxidative stress and GSH dynamics,
ATP dynamics, drug and bile salt concentrations,
liver mass dynamics; (3) clinical output of drug,
GSH and bile concentrations in blood, plasma
concentrations of ALT, AST, bilirubin, keratin 18,Biopharm. Drug Dispos. 35: 1–14 (2014)
DOI: 10.1002/bdd
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focuses on hepatic GSH depletion, mitochondrial
injury caused by reactive metabolites, adverse
impact on hepatic cell cycle and the release of bio-
markers into the blood. Detailed data at various
levels of this multi-scale model including metabo-
lism parameters of Vmax and Km and blood and
serum markers were curated and compiled from
various sources including the literature. Such a
comprehensive model is useful for the continuous
improvement on the level of sophistication to
increase the prediction power and for simulation
at the population level if genetic mutation can be
integrated.
Systems of molecular pathways and networks are
intertwined with one another via coordination and
regulated cross-talk, from cells to organs/tissues
to the body, to maintain the homeostatic integrity
of the human body. Take the mitochondrion for in-
stance, its physiological homeostasis is maintained
and regulated by its own genome [15] as well as
nuclear genes [16], although its physical structure
appears to be isolated from the nucleus or other or-
ganelles. These complex microscopic interactions
could be determined by temporal transcriptomic
analysis to reveal the molecular pathways involved.
For example, statins currently on the market cause
treatment-related myopathy and rhabdomyolysis
in rare cases [1]. Perturbation of eicosanoid synthe-
sis and phospholipase C pathways by high dose
statins was observed in patients’ skeletal muscles,
and was linked to changes in patients’ plasma
lipidemic proﬁles [17]. Integration of systems
biology and genomics has gradually advanced
our understanding of the complexity of cellular
networks in relation to human diseases [18], espe-
cially genetic disorders [19]. A case–control study
of 188 age- and gender-matched coronary heart
disease (CHD) patients and 188 healthy subjects
identiﬁed multi-tissue drivers (Spi-B transcription
factor, SPIB and tumor necrosis factor receptor
superfamily, member 13C, TNFRSF13C) as well as
tissue-speciﬁc drivers (early B-cell factor 1, EBF1)
that were associated with the risk for developing
CHD. These driver genes were derived using co-
expression network analysis as well as leveraging
the previously published gene networks and
protein–protein interaction. These reports illustrate
that the pathway signatures underlying the effect of
drug could be associated statistically with relevantCopyright © 2013 John Wiley & Sons, Ltd.plasma and/or urinary biomarkers. So could the
gene signatures be found for a clinically deﬁned dis-
ease phenotype via systems pharmacology analysis.
There are several publicly accessible transcriptomic
databases [20,21] available for hypothesis-generating
analytics of the extended pharmacological network,
and for delineating the pathways perturbed by
a drug within a speciﬁc cellular context. Post-
translational modiﬁcations, however, further in-
crease the complexity of biological networks
throughout the life cycle of the cell. A protein can
exist in more than one isoform in vivo, with one
particular isoform expressed in a speciﬁc organ.
Ryanodine receptor 2 (Ryr2), for example, is
preferentially expressed in cardiac myocytes and
was reportedly the off-target of daunorubicin
cardiotoxicity [22], whereasRyr3, a skeletal muscle
isoform, was linked to statin-induced myopathy
[23] and up-regulated in cerivastatin-induced
rhabdomyolysis [24]. A precise mapping of the
speciﬁc protein isoform(s) in each organ is criti-
cally important for deﬁning the multi-organ or
organ-speciﬁc systems pharmacology network of
a drug for proper linkage to respective biomarkers.Framework for Systems Pharmacology
Modeling
The accumulated knowledge and data from ap-
proved [1] and withdrawn drugs may prove use-
ful for bridging the gap between preclinical and
clinical outcomes for new drug candidates. One
can leverage the publicly accessible, curated data-
bases and knowledge-bases of pathways [25,26],
cellular transcriptomic signatures [20], chemogenomic
signatures of FDA-approved drugs and other chemi-
cal entities on a genome-wide scale in several cell lines
[20], gene–drug interactions [1,27] and gene–disease
association [19] studies to conduct integrated systems
pharmacology modeling [7]. The caveat, though,
is that inconsistency exists among pathway and
interactome databases [26]. Hence, one would
need to apply prior knowledge when applying
these databases for hypothesis generation. Multi-
plex measurements of transcriptomic, imaging
and cellular phenotypic readouts are available to
depict the beneﬁcial or toxic effect of a drug from
cellular pathways to organelles to cells in a com-
pendium of immortalized cell lines, primary cellBiopharm. Drug Dispos. 35: 1–14 (2014)
DOI: 10.1002/bdd
4 J.P.F. BAI ET AL.types, human pluripotent stem cells and induced
pluripotent stem cells. In a systems-pharmacology
model, the cellular pathways perturbed by a drug
and its treatment-related beneﬁts (on-target) or
adverse effects (off-target) can conceivably be
bridged by an array of molecular signatures, or-
ganelle phenotypes, cellular phenotypes and clini-
cal biomarkers. With proper experimental set-ups,
advances in next generation sequencing of clinical
samples [28] and imaging of cellular phenotypes/
biomarkers [29] are expected to provide the much
needed data to bridge the preclinical–clinical gap
for systems pharmacology modeling. Bordbar
et al. studied intercellular interaction by leveraging
a genome-scale metabolic network for adipocytes,
hepatocytes and myocytes each [30]. A blood com-
partment was added to connect the three tissues to
form a multi-tissue model, and was used to under-
stand perturbation of metabolic activity in the
context of obesity. With the metabolomic results
accumulated in the literature, modeling metabolic
perturbation using a genome-scale metabolic net-
work will facilitate our understanding of diseases
and the prediction of drug toxicity.Figure 1. Following administration, a drug can cause treatment-rela
and biomarkers. In systems pharmacology analysis/modeling, a mu
olites produced in the liver are circulated to multiple organs depen
physiological and biochemical homeostasis of the cell that is genet
The drug and/or its major metabolites can cause similar biochemic
perturbations in some organs, which are manifested in a range of c
measurable blood and urinary biomarkers. A highest statistical rig
biomarkers at the systemic level to a speciﬁc biochemical conseque
Copyright © 2013 John Wiley & Sons, Ltd.Following administration, a drug and its major
metabolites will interact with multiple levels
throughout the hierarchical structure of a human
body, from molecular networks to cells and to or-
gans, as illustrated in Figure 1. At the microscopic
cell and pathway levels, a drug can perturb bio-
chemical and physiological homeostasis, leading
to clinical manifestations of its treatment-associated
adverse drug reactions, including symptoms, and
serum as well as urinary biomarkers. There could
be similar intracellular perturbations caused by a
drug across multiple organs due to the same toxic
mechanisms, resulting in an array of adverse drug
reactions associated with individual organs or
systems. There also could be different intracellular
perturbations due to different toxic mechanisms as
a result of speciﬁc protein isoforms in some individ-
ual organs. For any statistical linkage with the
observed clinical phenotypes in the form of
symptoms and/or measureable biomarkers, the
statistical rigor imposed on systems pharmacol-
ogy-based modeling and linkage would reach the
highest, as compared with other linkages between
any two lower levels in the human body hierarchy.ted adverse reactions that are detected by systemic phenotypes
lti-scale approach is needed where a drug and its major metab-
ding on their unique ADME proﬁles, and cause perturbation of
ically unique resulting from inherited genetic polymorphisms.
al perturbations across multiple organs or unique biochemical
linical phenotypes of mild or severe symptoms associated with
or is needed to link each organ phenotype along with relevant
nce resulting from perturbation of an intracellular network
Biopharm. Drug Dispos. 35: 1–14 (2014)
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sessment can leverage accumulated pharmacoki-
netic and physiologically based pharmacokinetic
modeling technologies, curated data and knowl-
edge for a multi-scale modeling from pathway to
clinical phenotype and biomarker.Associating Clinical Phenotype of Organ
Toxicity with Cellular/Organelle Phenotype
Drug-induced mitochondrial hepatotoxicity
The cell consists of organelles that communicate
with one another to form a tightly controlled com-
munity; intracellular organelles include mitochon-
dria, endosomes, lysosomes, ribosomes, nucleus
and golgi apparatus. Mitochondria are the power-
house of the cell, and the number of mitochondria
depends on the cell type and its energy requirement.
Mitochondria are the most abundant organelles in
hepatocytes accounting for 20% of the hepatocyte
volume. An individual hepatocyte contains nearly
1000 individual mitochondria whose dominant role
is oxidative phosphorylation and maintaining en-
ergy balance [31]. The intracellular ATP generated
by mitochondria is essential for various cellularTable 1. Hepatotoxic drugs associated with mitochondrial injury
Drug (ref) Phenotype
Tetracyline [35] Microvesicular steatosis with minimal
inﬂammation
Aspirin [80] Reye’s syndrome; microvesicular steato
absence of glycogen on biopsy; frequen
with cerebral edema, minimal bilirubin
Valproate [33,81] Microvesicular steatosis with necrosis;
progressive ﬁbrosis with cholestasis seen
patients
Fialuridine [82] Direct inhibition of mitochondrial DNA
replication
Stavudine (d4T) [36,83] Microvesicular (early) or macrovesicula
steatosis with minimal inﬂammation; ra
progression to liver failure
Didanosine (ddI) [38,84] Microvesicular steatosis with minimal
inﬂammation; may also cause acute
hepatocellular necrosis with jaundice
Linezolid [85] Inhibits mitochondrial protein synthesis
decrease protein function; lactic acidosis
neuropathy
Tamoxifen [37] Concentrated in mitochondrial matrix a
inhibits mitochondrial ß-oxidation and
respiration. Macrovesicular steatosis,
steatohepatitis, and cirrhosis; acute live
very infrequent
Copyright © 2013 John Wiley & Sons, Ltd.functions including bile secretion, gluconeogenesis,
protein synthesis and ureagenesis. When hepatic
mitochondrial function is impaired clinical manifes-
tations may include lactic acidosis, hypoglycemia,
hypoprothrombinemia and hyperammonemia.
Drugs with known or suspected mitochondrial
mechanismsof hepatotoxicity are shown in Table 1.
ATP depletion can lead to liver cell necrosis or
apoptosis via the release of cytochrome c into the
hepatocyte cytosol. With rapid inhibition of the
respiratory chain, there may be inadequate time
for hepatic steatosis to develop as is seen with
acetaminophen hepatotoxicity. Acetaminophen can
cause mitochondrial permeability transition (MPT).
Opening of the permeability transition pores is an
irreversible devastating event, leading to mito-
chondrial depolarization and cell death. The
toxicological network underlying acetaminophen
hepatoxicity includes inhibition of pro-survival
pathways of NF-kappaB and activation of tumor
necrosis factor, causing MPT, mitochondrial injury,
loss of cell integrity, apoptosis or necrosis.
Other drugs disrupt the mitochondrial function
by inhibiting mitochondrial DNA transcription or
replication as is seenwith the dideoxynucleoside an-
alogues. Normally, DNA polymerases do not allowClinical presentation
High doses given i.v. or i.m. for 3 to 10days in late
pregnancy, early post-partum and renal failure
patients
sis and
tly fatal
elevation
Antecedent viral illness in children such as
inﬂuenza or varicella with fever and anorexia
in some
More common in infants and individuals with
inherited mitochondrial disorders; frequently
within 1 to 3months of drug initiation
Presented after 2months of daily use in chronic
HBV patients
r (later)
pid
2 to 5months after initiation in HIV+; can also
present with cirrhosis/non-cirrhotic portal HTN;
risk factors include pre-existing liver disease,
female gender, obesity and alcohol
Risk factors include pre-existing liver disease,
obesity and alcohol; may present as non-cirrhotic
portal HTN
and can
with
Antibiotic to treat resistant Gram-positive cocci
nd
r injury
Anti-estrogenic used as adjunctive therapy for
breast cancer; up to 30% develop NAFLD/ NASH
with prolonged treatment
Biopharm. Drug Dispos. 35: 1–14 (2014)
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However, the DNA polymerase gamma (γ) does
not prevent these drugs from being incorporated
into mitochondrial DNA and over time these chain
terminators can lead to a depletion of mtDNA.
Zalcitabine and lamivudine inhibit mitochondrial
DNApolymerase gamma activity, and consequently
reduce mitochondrial DNA mass [32]. These drugs
also cause peripheral neuropathy, lipodystrophy,
myopathy and lactic acidosis [1]. For unclear rea-
sons, the nucleoside analogues have differential ef-
fects on mtDNA replication with zalcitabine (ddC),
didanosine (DDI) and stavudine (d4T) being more
likely to lead to mtDNA depletion than zidovudine
(AZT), lamivudine (3TC) and abacavir (ABC) [32].
Individuals with inherited or acquired mitochon-
drial defects may be more susceptible to liver injury
from certain drugs as has been reported with
valproate hepatotoxicity [33]. In addition, malnu-
trition and certain disease states including viral
infections may lead to circumstances that increase
the risk of drug-induced mitochondrial toxicity.
Severe impairment of fatty acid oxidation leads to
hepatic steatosis when accumulated free fatty acids
that are taken up or synthesized by the liver become
esteriﬁed into triglycerides in the hepatocyte cyto-
plasm. Acute impairment of fatty-acid ß-oxidation
leads to the formation of microvesicular steatosis
wherein numerous tiny lipid vesicles are formed
around the nucleus and have a ‘foamy’ appearance.
In contrast, when ß-oxidation impairment is more
chronic, the small vesicles can coalesce into larger
fat droplets that then become eccentric in the hepa-
tocyte. Therefore, incorporation of cellular toxicity
kinetics would facilitate informed systems pharma-
cology modeling. The choice of an appropriate cell
model will, however, be very critical if a speciﬁc bio-
chemical or molecular pathway is to be properly
linked to speciﬁc cellular and clinical phenotypes.
The HepG1 and HuH7 cell lines, for example, have
low capacity to oxidize long-chain fatty acids and
will not be suitable to study how stavudine and
valproic acid cause intracellular lipid accumulations
leading to fatty liver [34].Clinical phenotypes
Acute and severe impairment of mitochondrial
function can lead to acute fatty liver with lactic
acidosis which is a distinctive and frequentlyCopyright © 2013 John Wiley & Sons, Ltd.dramatic clinical syndrome associated with a high
rate of morbidity and mortality if not promptly
recognized and treated. The hallmark of this
syndrome is small droplets of fat (microvesicular)
that accumulate in the hepatocyte cytosol from
impaired ß-oxidation of fatty acids as reported
with tetracycline and valproic acid [33,35]. In con-
trast, drugs, toxins and disease states that lead to
partial but chronic depletion of mitochondrial
function can lead to the accumulation of large fat
droplets (macrovesicular) that are often eccentri-
cally located in the cell. Drugs associated with
the latter phenotype include tamoxifen and the
dideoxynucleoside analogues used to treat HIV
infection [36–38].Clinical features at presentation
Patients with acute fatty liver typically have a sys-
temic lactic acidosis due to impaired mitochondrial
function as well as stupor, coma, encephalopathy,
hyperammonemia and coagulopathy. Drugs that
directly inhibit mitochondrial function or protein
synthesis typically present within 1month of drug
initiation. Initial clinical symptoms are frequently
non-speciﬁc and vague such as nausea, anorexia
and abdominal pain and typically proceed the liver
injury by 1 to 4weeks. With lactic acidosis, some
patients may present with shortness of breath,
muscle weakness or impaired mental status.
Jaundice is rarely present at drug-induced liver
injury (DILI) onset and is usuallymild. Serum amino-
transferase concentrations are usually onlyminimally
elevated (< 5 to 10 × ULN) at DILI onset, despite
the presence of concomitant hypoalbuminemia,
hypoprothrombinemia, hyperammonemia and
hypoglycemia. Because the mitochondrial dys-
function is usually not isolated to the liver, many
patients may have myopathy, neuropathy or
pancreatitis prior to or after the liver injury onset.
Patients with sub-acute or chronic drug-induced
mitochondrial liver injury are more likely to pres-
ent withmild to moderate transaminase elevations
over many months without prominent lactic aci-
dosis, hypoprothrombinemia or jaundice. Clinical
symptoms are also likely to be vague and non-
speciﬁc. As a result, a liver biopsy may be needed
to establish a diagnosis wherein mixed or
macrovesicular steatosis with variable degrees of
inﬂammation, cholestasis and ﬁbrosis may beBiopharm. Drug Dispos. 35: 1–14 (2014)
DOI: 10.1002/bdd
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consider in patients with either an acute or chronic
drug-induced mitochondrial hepatotoxicity syn-
drome are alcoholic and non-alcoholic fatty liver
disease or sudden weight gain due to corticoste-
roid use. So, careful assessment and ascertainment
of drug-induced liver toxicity is as important for
systems pharmacology modeling as the quality of
network and pathway data.Other drug-induced organ toxicities
Valproic acid can also cause intracellular accumula-
tion of lipid droplets in skeletal muscles that may
result in rhabdomyolysis [39,40]. Cyclosporine, an
immunosuppressant used in organ transplant
recipients, is nephrotoxic, and reportedly causes
autophagic vacuoles in rat kidney cells [41]. Cyclo-
sporine therapy increases BUN and serum creatine
concentrations, causes renal tubular structural
damage and globally reduces renal function in
patients [1]. Statins are associated with a functional
decline and muscle cramping in patients with
amyotrophic lateral sclerosis (ALS) [42]. Fuvastatin
depletes spinal cord motor neurons and causes the
degeneration of neurons [43]. This observation is
in agreement with that observed in ALS patients
on statins, although further studies are needed to
establish the mechanistic linkage. In patients who
developed hyperlactatemia during treatment with
linezolid, decreased mitochondria mass and pro-
tein content were observed in their peripheral
blood mononuclear cells, although mitochondrial
membrane potential or intact cell oxidative capacity
did not change signiﬁcantly [44]. Mitochondrial
permeability transition (MPT) has also been associ-
ated with cardiotoxicity of doxorubicin [45] and re-
nal toxicity of non-steroid anti-inﬂammatory drugs
[46]. Cerivastatin was withdrawn from the market
due to its treatment-related rhabdomyolysis, kid-
ney failure and deaths [47]. Subsequently, various
statins were shown to reduce the mitochondrial
ATP concentration in myoblasts [4]. Elevated
plasma creatine phosphokinase (CPK) levels were
observed in patients who experience myopathy or
myalgia or rhabdomyolysis with the highest eleva-
tion in patients with statin-induced rhabdomyoly-
sis [1]. Apparently, statin induced mitochondrial
toxicity was felt to be responsible for these adverse
muscle reactions.Copyright © 2013 John Wiley & Sons, Ltd.Summary
Cellular phenotypes can be useful pharmacody-
namic endpoints for bridging cell/organ and clinical
phenotypes. Amixed array of common and different
molecular events can lead to mitochondrial toxicity,
causing irreversible MPT, cell death and devastating
injury to various organs [45,46,48]. A library of drugs
that can causemitochondrial toxicity, alongwith their
individualmolecular signatures in relevant cell lines/
tissues and clinical biomarkers, would be highly
useful for modeling and establishing a predictive
model for developing safer new drugs.Consideration of Immune Surveillance
The innate immune systemplays a key role in drug-
induced organ injury. Accumulated evidence has
incriminated toll-like receptor 4 in acetaminophen-
induced acute liver and lung injury [49]. Dam-
aged mitochondria are usually digested in the
lysosomal-autophagy system. Lysosomes can be-
come overwhelmed, when extensive mitochondrial
damage occurs, resulting in an accumulation of
mitochondrial DNAs that could eventually escape
lysosomal digestion. Mitochondrial DNAs that es-
cape digestion by lysosome-autophagy processing
reportedly trigger toll-like receptor 9-mediated in-
ﬂammatory responses in mouse cardiomyocytes,
resulting in myocarditis and cardiomyopathy [50].
Transforming growth factor-β controls mitochon-
drial metabolism via receptors on the plasmamem-
brane; its signaling pathways are involved in renal
and liver diseases [51] and play a role in chemical-
induced toxicity [52]. Human macrophage-lung
epithelial cell co-cultures were used for evaluating
the effects of environmental toxins [53], and such
a co-culture system could conceivably be useful
for evaluating drug toxicity. In short, the cross-talk
among circulating immune cells, their secreted
cytokines and individual organ resident cells con-
tribute to clinical symptoms and biomarkers in the
context of drug toxicity. Consideration of immune
participation in modeling drug safety is important,
and such modeling could be greatly aided by cu-
rated pathways reﬂective of immune participation
(Figure 2), which can be readily adopted [25], if
conﬁrmed to be adequate, and incorporated into
the model.Biopharm. Drug Dispos. 35: 1–14 (2014)
DOI: 10.1002/bdd
Figure 2. Participation of immune components should be included when modeling or analysing drug toxicity. There are curated
immune pathways available for reference. In the process of immune responses to abnormal proteins generated due to a drug’s
toxicity, proteasomes (a) are involved in degrading abnormal proteins and generating antigenic peptides. The antigenic peptides
can cause a cascade of immune responses through toll-like receptor signaling pathway (b) and/or (c) cytokine signaling pathway.
Pathways adopted from http://www.genome.jp/kegg/kegg1.htm
8 J.P.F. BAI ET AL.Consideration of Genetic Polymorphisms in
Perturbed Biochemical Networks
Genetic polymorphisms of ADME enzymes and
transporters [27] contribute to the extent of vari-
ability in exposure–response relationship of drug
and to drug–drug interaction [1]. There are ethnicity-
related differences in drug exposure and responses
resulting from ADME enzymes and transporters,
as well as in HLA allele related adverse reactions
[27,54]. Somatic mutations and epigenetic changes
could further alter an individual’s phenotypic
characteristics and result in diseases [55]. Epige-
netic mutations could conceivably contribute to
inter-subject variability in the efﬁcacy and safetyCopyright © 2013 John Wiley & Sons, Ltd.of a drug; however, their impact is not well under-
stood. Mutations that result in partially reduced
activities of multiple components in the pathways
involved in intracellular physiological homeosta-
sis could lead to the occurrence of disease [56].
This notion could be applied to understanding
the effect of drug action since a drug can inadver-
tently jeopardize the functions of genetically
impaired proteins in patients who carry those
mutations. The networks of genes and proteins
involved in individual genetic diseases with simi-
lar clinical phenotypes appear to be associated
among one another [16], further expanding the
universe of speciﬁc disease-related genes [19] and
proteins [57].Biopharm. Drug Dispos. 35: 1–14 (2014)
DOI: 10.1002/bdd
Figure 2. Continued
9SYSTEMS PHARMACOLOGY MODELING/ANALYSIS OF DRUG EFFECTSThe clinical phenotypes associated with a speciﬁc
drug toxicity could be similar, to a varying degree,
to those observed in a genetic disorder [1,19,58,59].Copyright © 2013 John Wiley & Sons, Ltd.Genetic disorders of McArdle’s disease and
Duchenne’s muscular dystrophy can lead to rhabdo-
myolysis and cause patients to suffer from tea-coloredBiopharm. Drug Dispos. 35: 1–14 (2014)
DOI: 10.1002/bdd
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rhabdomyolysis can also lead to these clinical mani-
festations [60]. Drug treatment could exacerbate
the symptoms of a certain genetic disorder or cause
a silent genetic mutation to manifest clinically [61].
One such gene–drug interaction leading to drug-
induced rhabdomyolysis is valproic acid and carni-
tine palmitoyltransferase 2 (CPT II) [61]. Determina-
tion of CPT II deﬁciency should be considered in
patients who need to take drugs that would affect
the biochemical network involving CPT II to prevent
drug-induced myopathy and rhabdomyolysis [62].
Pathway, network and cellular perturbations caused
by a drug and by a loss of function mutation of a
gene could be similar, as could their respective clini-
cal symptoms and circulating biomarkers [1,19,58].
Therefore, leveraging the known wealth of genetic
polymorphisms [59] could potentially guide map-
ping of individual systems pharmacology networks
of drug [7] to respective safety biomarkers, as shown
in Figure 3. Incorporation of mutations in relevant
biochemical pathway genes would increase the pre-
dictive power of systems pharmacology modeling
with respect to the efﬁcacy/risk ratio of a drug.Mitochondrial Toxicity-Centric Modeling
Mitochondria are the epicenter of drug-induced
organ toxicity. Different mitochondrial toxicity
mechanisms could lead to distinct clinical adverseFigure 3. Leveraging the known genetic diseases and their individu
effects of drug via technologies of machine learning and modeling
Copyright © 2013 John Wiley & Sons, Ltd.phenotypes in the same organ [40,48,63], while a sim-
ilar mitochondrial toxicity seems to cause a similar
organ toxicity [1,34,64]. Relationships exist between
cellular toxicity and clinical adverse phenotypes,
such as inhibition of mitochondrial fatty acid oxida-
tion leading to intracellular accumulation of lipid
droplets in hepatocytes and fatty liver [1,34,64].
Reactive oxygen species generated by damaged
mitochondria is one particularly interesting area
in drug toxicity, and one that is amenable to quan-
titative mechanistic modeling [65]. During normal
ATP production through oxidative phosphoryla-
tion, 0.4–4% of all consumed oxygen is converted
to superoxide radical [O2- ] [66]. In normal physiol-
ogy, the superoxide radical is largely reduced
through a number of enzyme-catalysed steps,
with the oxygen molecule ending in water; how-
ever, when this cascade of reactions is disrupted
by a drug, then free radicals can accumulate and
damage mitochondria, leading to sub-level func-
tioning of mitochondria, even higher production
of ROS and eventually mitophagy, which can lead
to cell death as in Parkinson’s and Huntington’s
disease [67]. This process is represented by a kinetic
model simulating ROS-induced mitochondrial
death in Parkinson’s disease [65].
ROS also damages the proteins, lipids and genes
responsible for the normal functioning of the mito-
chondria [68] as observed in a number of cancers.
ROS removes the sulfhydryl group of pyruvate ki-
nase isoform 2 [69] resulting in sub-level functioningal clinical biomarkers and phenotypes to assess and predict the
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DOI: 10.1002/bdd
11SYSTEMS PHARMACOLOGY MODELING/ANALYSIS OF DRUG EFFECTSofmitochondria, leading to the production of lactate
and creating an acidic microenvironment that can
enhance tumor growth. ROS inﬂicted DNA damage
and deﬁcient repair mechanism has been associated
with a risk of cancer and other diseases such as auto-
immune disease [70,71]. Additionally, ROS pro-
motes tumor growth through mitogen activated
protein kinase (MAPK)mediated signaling cascades
[72]. MAPK signaling modulated the expression of
genes that are involved in proliferation,metabolism,
programmed cell death and others [73]. Thus, drugs
that affect the ability of the cell to copewith ROS can
lead to a myriad of potential health problems.
Higher levels of ROS can cause extensive mitochon-
drial damage and lead to a wide spectrum of mala-
dies ranging from neurodegenerative to various
cancers. ROS inmitochondria has been studiedwith
a concentrated focus on disease origination over a
long period of time, however, drug-induced ROS
mediated mitochondrial damage has lacked atten-
tion. This presents an opportunity to leverage a
knowledge of ROS andmitochondrial damage to re-
duce future drug attrition rates.Future Perspectives
Leveraging systems biology to delineate the ef-
fects of a drug from its on-target(s) beneﬁcial
effect and off-target(s) adverse effects through
the systems pathways and networks would aid
our understanding and assessment of its safety
and overall therapeutic index. Current scientiﬁc
advances and accumulated knowledge of disease
[19], clinical toxicity [1] and systems biology [25]
have presented opportunities to extend traditional
pharmacokinetic and pharmacodynamicmodeling/
analysis to execute systems pharmacology model-
ing. In such modeling pharmacological responses
at the pathway/network, organelle and organ
levels are integrated through incorporation of
relevant bridging biomarkers [7,74]. Conceivably,
systems pharmacology network modeling may
not involve all intracellular networks at the same
level and depth of complexity as systems biology,
but insteadmay only require capturing the portion
of intracellular networks that a drug affects. Sys-
tems pharmacology modeling of the clinical phe-
notypes manifested during a drug therapy would
advance at a faster pace if one can leverageCopyright © 2013 John Wiley & Sons, Ltd.systems biology and cellular phenotypes in rela-
tion to perturbation of cellular networks and corre-
sponding biochemical consequences. Modeling a
speciﬁc organelle phenotype as the surrogate of a
deﬁned cellular phenotype, under a prior deﬁned
speciﬁcity and sensitivity, for the statistical linkage
to a clinical phenotype could enable early predic-
tion of the toxicity proﬁle of a drug, and help
to screen out toxic drugs prior to phase 2 and 3
clinical trials. Compiling a database of use cases
with respect to a speciﬁc surrogate would surely
be the beginning step to ascertain the linkage
between surrogate marker(s) and a clinical pheno-
type. Systems-pharmacology modeling with cu-
rated individual components would be the best
approach to handling the complex system of organ
toxicity. Such approaches would beneﬁt also from
integration with genome-scale networks such as
those that have been built for metabolism in
humans generally [75,76], as well as for speciﬁc or-
gans and cell types [77–79]. Both the molecular
signature in a speciﬁc cell type of an organ and the
panel of cellular signatures following exposure to a
drug adequately covering all critical cell types of
human organs would help to deﬁne the systems-
pharmacology network of an array of pharmacody-
namic responses following its administration.
In summary, systems pharmacology modeling
is essential for linking systems networks that are
affected by a drug to its treatment-associated
clinical measurable biomarkers and phenotypes
through speciﬁed statistical criteria and consider-
ation of gene–drug interactions and immune sys-
tem elements. Such approaches, if applied across
all the pharmacological classes of marketed drugs,
will improve the yield of future drug products
with an adequate beneﬁt/risk ratio.Acknowledgements
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